Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance.
The incidence of infections caused by resistant Gram-positive pathogens is increasing, while emergence of vancomycin resistance is reducing the number of therapeutic options. New agents are being rapidly evaluated as candidates to replace vancomycin; some of the most promising include semisynthetic glycopeptides, quinupristin-dalfopristin, oxazolidinones and everninomycins. Alternative strategies, including immunization and therapeutic vaccines, may also have a role.
Nicas
T I
TI
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. nicas_thalia_r@lilly.com
Zeckel
M L
ML
Braun
D K
DK
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D016908:Gram-Positive Bacterial Infections / Q000628:therapy*; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D015394:Molecular Structure; D014640:Vancomycin / Q000737:chemistry / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin